Annuncio pubblicitario
Italia markets open in 57 minutes

  • Dow Jones

    38.460,92
    -42,77 (-0,11%)
     

  • Nasdaq

    15.712,75
    +16,11 (+0,10%)
     

  • Nikkei 225

    37.633,47
    -826,61 (-2,15%)
     

  • EUR/USD

    1,0716
    +0,0015 (+0,14%)
     

  • Bitcoin EUR

    59.939,05
    -2.358,54 (-3,79%)
     

  • CMC Crypto 200

    1.390,87
    +8,30 (+0,60%)
     

  • HANG SENG

    17.244,51
    +43,24 (+0,25%)
     

  • S&P 500

    5.071,63
    +1,08 (+0,02%)
     

TG Therapeutics to Host Conference Call on Third Quarter 2022 Financial Results and Business Update

TG Therapeutics, Inc.
·1 minuto per la lettura
TG Therapeutics, Inc.
TG Therapeutics, Inc.

Conference call to be held Thursday, November 10, 2022 at 8:30 AM ET

NEW YORK, Nov. 08, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held on Thursday, November 10, 2022 at 8:30 AM ET to discuss results for the third quarter of 2022. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.

In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.

ANNUNCIO PUBBLICITARIO

TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.

ABOUT TG THERAPEUTICS 
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS). For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and Linkedin.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6